Our research develops fast, affordable molecular tests that answer clinical questions: which cancer treatment fits a tumor, who carries a higher inherited risk for the diseases of aging, and which infection or variant a patient has. In 2026 we adopted a three-year research plan (2026–2029) in molecular diagnostics and computational pathology.
A five-color multiplex real-time PCR assay using ARMS primers and probes to report KRAS and BRAF (V600E / V600K) status in colorectal cancer in about four hours, on widely used PCR instruments. It received the Best Clinical Poster award at the ASCP 2024 Annual Meeting.
We are also developing breast cancer sequencing library workflows on Illumina short-read and Oxford Nanopore long-read platforms, comparing the two on the same samples.
Cancer Genomics ResearchTesting for healthy adults that combines inherited risk for the major diseases of aging (cancer, cardiovascular, brain, liver and kidney disease) with blood-based markers of biological aging.
Our lab also studies how biological functions are regulated during aging, including reversible aging mechanisms and senolytics.
Longevity Genetic TestingMultiplex real-time PCR assays that detect SARS-CoV-2 and distinguish variants of concern such as Omicron and Delta, and a lateral-flow rapid antigen test. This work led to pre-EUA submissions to the U.S. FDA (2021 and 2022) and to patents and patent applications.
PatentsThe research plan adds computational analysis of pathology and molecular data to our assay work, building on our founder's training as a board-certified pathologist.
We welcome research collaborations with laboratories, clinicians and institutions in molecular diagnostics, cancer genomics and computational pathology.
Contact research@cellgenemedix.com or visit our contact page.
Assays under development are for research use only. Not for diagnostic use. Not cleared or approved by the U.S. FDA.
